NCT03573700 2025-11-18
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
Clinical Trials
15 trialsNCT03050190 2025-09-08
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT03125577 2025-09-08
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT06834529 2025-02-19
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences
Phase 1/2 Recruiting
NCT06762431 2025-01-07
VTB-CLL002
Vitebsk Regional Clinical Cancer Centre
Phase 1/2 Enrolling by invitation
NCT03098355 2024-03-18
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
Zhujiang Hospital
Phase 1/2 Withdrawn
NCT05932173 2023-07-11
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2 Unknown
NCT05570188 2022-11-30
Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies
Kunming Hope of Health Hospital
Phase 1/2 Withdrawn
NCT02933320 2021-07-08
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
Cancer Research UK
Phase 1/2 Completed
NCT04747093 2021-02-10
Induced-T Cell Like NK Cells for B Cell Malignancies
Nanfang Hospital, Southern Medical University
Phase 1/2 Unknown
NCT01626495 2020-03-23
Pedi CART19
University of Pennsylvania
Phase 1/2 Completed
NCT04016129 2019-09-19
CAR-T Immunotherapy Targeting CD19- ALL
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Unknown
NCT03398967 2018-01-16
A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT02132624 2017-10-30
CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
Uppsala University
Phase 1/2 Completed
NCT03166878 2017-06-23
A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
Chinese PLA General Hospital
Phase 1/2 Unknown